4//SEC Filing
Broom Colin MD 4
Accession 0001104659-20-097717
CIK 0001641640other
Filed
Aug 20, 8:00 PM ET
Accepted
Aug 21, 7:02 PM ET
Size
8.8 KB
Accession
0001104659-20-097717
Insider Transaction Report
Form 4
Broom Colin MD
Chief Executive Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2020-08-19+33,750→ 260,000 total - Sale
Ordinary Shares
2020-08-20$0.65/sh−11,064$7,165→ 248,936 total - Exercise/Conversion
Restricted Share Units
2020-08-19−33,750→ 0 total→ Ordinary Shares (33,750 underlying)
Footnotes (2)
- [F1]The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units.
- [F2]On January 31, 2018, Nabriva Therapeutics plc (the "Issuer") granted the reporting person 67,500 restricted share units ("RSUs"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the "Performance Condition"), and the remaining fifty percent (50%) of the RSUs vested on the one (1)-year anniversary of the Performance Condition.
Documents
Issuer
Nabriva Therapeutics plc
CIK 0001641640
Entity typeother
Related Parties
1- filerCIK 0001289946
Filing Metadata
- Form type
- 4
- Filed
- Aug 20, 8:00 PM ET
- Accepted
- Aug 21, 7:02 PM ET
- Size
- 8.8 KB